Annexin A2 Versus a-Fetoprotein (AFP) as an Efficient Diagnostic Serum Marker for Hepatocellular Carcinoma
/ 0
- Details
- Category: Vol. 85, September 2017
- Hits: 461
Annexin A2 Versus a-Fetoprotein (AFP) as an Efficient Diagnostic Serum Marker for Hepatocellular Carcinoma, EHAB M. REYAD, EHSAN H. ABD EL-BARI, SELIM W. MORCOUS and SAHAR Z. MAKLAD
Abstract
Background: The burden of hepatocellular carcinoma (HCC) has been increasing in Egypt due to high prevalence of HCV in Egypt. Early detection of HCC is difficult due to lack of reliable markers.
Objective: This work was designated to assess the role of annexin A2 versus the widely used AFP for detection of HCC, especially in the early stage of the disease.
Patients and Methods: This study included 24 patients with chronic hepatitis C, 26 patients with cirrhosis, 50 HCC patients and 20 healthy controls. All participants performed thorough assessment and laboratory investigations. Serum level of annexin A2 was detected using ELISA. Clinicopatho-logical characteristics of circulating annexin A2 expression were analyzed, and its diagnostic efficiency in HCC was evaluated versus AFP.
Results: We found that annexin A2 was significantly increased in the sera of HCC patients (median, 29.8ng/mL) compared with the cirrhotic (median, 13.8ng/mL, p=0.03), chronic hepatitis C (median, 10.8 ng/mL, p<0.001) and healthy controls (median, 11.2ng/mL, p<0.001). Importantly, annexin A2 levels in early stage HCC cases were not significantly different from that of cirrhotic patients (p=0.08) and late stage HCC cases (median, 30.7ng/mL, p=0.07). Area under the receiver-operating characteristic curve was 0.75 for annexin A2 and 0.83 for AFP. Combining detection of two markers could not improve the diagnostic efficiency for HCC. Serum annexin A2 expression in HCC patients was associated with AFP level (p<0.001), but was not correlated with patient sex, age, tumor size or tumor BCLC staging system.
Conclusion: Annexin A2 may not be a good diagnostic biomarker for HCC.